Home » News

News

GLP‑1 agonists
Semaglutide vs Tirzepatide vs Retatrutide

Semaglutide

Approved and widely used in China, with the most mature data.

Indications 

  • Type 2 diabetes patients
  • Poor blood glucose control; can be used alone or with other antidiabetic drugs.
  • Overweight / obese adults
  • BMI ≥ 24 kg/m² with at least one weight-related condition (hypertension, hyperlipidemia, fatty liver, etc.)
  • OR BMI ≥ 28 kg/m²

Features

  1. Moderately strong blood glucose lowering and weight loss effects
  2. Most extensive safety data
  3. Covered by medical insurance (for diabetes indication only)

Tirzepatide

GIP+GLP‑1 dual agonist; stronger than semaglutide.

Indications

  • Type 2 diabetes patients
  • Better glucose control than semaglutide.
  • Overweight / obese adults
  • Significantly greater weight loss than semaglutide.
  • Suitable for those wanting more weight reduction.

Features

  1. Strong effects on both glucose control and weight loss
  2. Side effects (nausea, diarrhea) may be more noticeable
  3. Approved and available in China

Retatrutide

GLP‑1/GIP/GCG triple agonist; currently the most potent class.

Important notes

  • Not yet approved in China
  • Only used in clinical trials or certain regions abroad

Theoretical indications

  • Type 2 diabetes
  • Obesity / severe obesity
  • Strongest weight loss effect among all GLP‑1 agents so far

Features

  1. Most potent effects, but long-term safety data are still being collected
  2. Not legally available or prescribable in China

Simple summary

  • Safe, stable, insurance-covered → semaglutide
  • Stronger glucose control + weight loss → tirzepatide
  • Retatrutide: not yet available in China; not recommended to purchase privately
ItemSemaglutideTirzepatideRetatrutide
ClassGLP‑1 receptor agonistGIP+GLP‑1 dual agonistGLP‑1/GIP/GCG triple agonist
Approved in ChinaApproved & availableApproved & availableNot approved
Main IndicationsType 2 diabetes, weight managementType 2 diabetes, weight managementType 2 diabetes, obesity (clinical stage)
Glucose controlStrongStrongerStrongest (trial data)
Weight lossStrongSignificantly strongerStrongest so far
Suitable forDiabetes, stable weight lossDiabetes, larger weight loss goalSevere obesity (studies abroad)
Common side effectsNausea, bloating, diarrhea, constipationNausea, diarrhea, decreased appetiteNausea, vomiting, diarrhea (may be higher)
InsuranceCovered for diabetesCovered for diabetesNot covered
AvailabilityHospitals, licensed pharmaciesHospitals, licensed pharmaciesNot legally available in China
Key pointsSafe, well‑establishedMore potent, reliable dataMost powerful, not approved in China

 

Share:

More Posts

SERMs vs Thyroid Hormones: Enclomiphene, Clomiphene, Tamoxifen, T3 & T4 — The Complete Comparison

This article clarifies the critical pharmacological differences between SERMs (Enclomiphene, Clomiphene, Tamoxifen) and thyroid hormones (T3, T4), two commonly confused families of hormone-modulating compounds. Many users mistakenly treat them as interchangeable “hormone optimizers” for stacking or substitution, which carries unnecessary physiological risks. This breakdown compares their molecular structures, receptor targets, and core regulatory pathways: SERMs act on estrogen receptors to modulate the HPG axis and endogenous testosterone output, while T3/T4 bind universal nuclear thyroid receptors to control basal metabolism, thermogenesis, and systemic cellular function. It further distinguishes Clomiphene’s dual-isomer composition from purified Enclomiphene, alongside Tamoxifen’s unique tissue-selective activity. This evidence-based guide eliminates common endocrine misconceptions and defines safe, research-only application boundaries for laboratory reference.

ISRIB A-17 Properties

ISRIB A-17: Properties, Advantages and Exclusive Research Applications Chemical Probes · ISR Pathway ISRIB A-17: Properties, Advantages and Exclusive Research Applications By Research Chemistry Team

CPHI China 2026

CPHI China 2026: NutraBiotech at Asia’s Largest Pharma Exhibition | SNIEC Shanghai Home / Blogs / Industry Events / CPHI China 2026 CPHI China 2026:

Send Us A Message